HCW Biologics Inc.
HCWB Healthcare Biotechnology
HCW Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54,200.00, down 97.9% from fiscal 2024. In the quarter to June 2026, revenue grew 1,954.6%, EPS grew 71.6%, free cash flow fell 20.8% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HCWB
HCW Biologics Inc. (HCWB) EV/Sales
As of 16 October 2026, HCW Biologics Inc. (HCWB) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.0× (December 2022) to 638× (April 2024); the current reading is higher than 29% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 134× | 1,204.06% |
| FY2024 | 10.3× | (36.59%) |
| FY2023 | 16.2× | 143.92% |
| FY2022 | 6.6× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.9× | 63.90% |
| Mar 2026 | 1.2× | (99.13%) |
| Dec 2025 | 134× | 290.96% |
| Sep 2025 | 34.2× | 149.62% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. compare | −19.2× |
| VIVS VivoSim Labs, Inc. compare | −7.4× |
| ONCO Onconetix, Inc. compare | −7.3× |
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| GOVX GeoVax Labs Inc. compare | −0.3× |
| SLXN Silexion Therapeutics Corp compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.6× |
| HCWB HCW Biologics Inc. | 1.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)